Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Lifeline Scientific (LSI)

  Print      Mail a friend

Monday 12 October, 2009

Lifeline Scientific

Award of Grants

RNS Number : 5715A
Lifeline Scientific, Inc
12 October 2009

Monday 12 October 2009

Lifeline Scientific, Inc.

("Lifeline" or the "Company")

Award of Grants

Lifeline Scientific, the medical technology company focused on commercialising its advanced organ preservation and transport systems, designed to address the global challenge of human donor organ shortages, announces today that its CTS division has been awarded US federal government grants totalling US $2.35 million which will be funded over the next two years.

The main grant and a supporting award are for the development of improved preservation methods for cells, tissues and organs for transplantation. Studies will be done in collaboration with academic research centers in the US. A third grant is for further development and testing of Lifeline's proprietary LifePort Pancreas Transporter technology and related solutions for pancreas preservation for islet transplantation.

The target of the main grant is to further the Company's efforts in the development of solutions principally for liver preservation. 

Today, liver preservation for transplantation has limitations with regard to preservation time and evaluation of livers prior to transplant, especially with livers from expanded criteria donors. Lifeline is hopeful that these studies can help lead to technology that provides longer storage periods with better quality and assessibility of the preserved tissue, potentially leading to increased availability of organs for transplant. Irreversible liver failure causes certain death unless a transplant can be obtained. There is a dramatic shortage of livers for transplant world wide, while official waiting lists made up of end-stage liver disease patients continue to grow substantially. 

The grant to support further testing and development of the LifePort Pancreas Transporter technology and related solutions is aimed at advancing efforts around islet transplantation, an emerging promising treatment for qualified patients with Type 1 Diabetes. In recent studies, machine preservation of pancreas via LifePort has been shown to improve both the yield and viability of islets derived from pancreas compared with conventional static cold storage.  

These grants will fund the bulk of the CTS division research efforts regarding organ, tissue, and cell preservation over the next 18-24 months.

David Kravitz, Chief Executive of Lifeline, said: 

"While we are delighted with the initial clinical success of our core product, the Lifeport Kidney Transporter, these grants will enable Lifeline to advance important research and development of our LifePort technology platform to help improve the recovery and preservation of other organs and tissues for transplantation. We are proud of the achievements of the Company's scientific leadership team and honoured by the recognition of their capabilities through these federal grant awards."


Lifeline Scientific, Inc.

+1 847 824 2420

David Kravitz, CEO

Seymour Pierce

+44 (0)20 7107 8000

Mark Percy / Huaizheng Peng / Sarah Jacobs

Financial Dynamics

+44 (0)20 7831 3113

Ben Brewerton / John Dineen

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t